Foscenvivint is under clinical development by Eisai and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Foscenvivint’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Colorectal Cancer

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Foscenvivint overview

Foscenvivint is under development for the treatment of HCV or HBV or NASH-induced decompensated cirrhosis, leukemia such as acute myeloid leukemia (AML), neuroendocrine tumors, chronic myeloid leukemia (CML), metastatic colorectal cancer, retinal fibrosis, adrenocortical carcinoma (ACC), gastrointestinal tumors such as small bowel carcinoma and gastrointestinal neuroendocrine tumors, desmoid tumors, anaplastic thyroid cancer (ATC), endometrial cancer, melanoma, myelodysplastic syndrome, colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic cancer, prostate cancer and ovarian cancer. The drug candidate is administered through intravenous and oral route. PRI-724 is a new chemical entity. It acts by targeting CBP/beta-catenin complex formation, and modulates the beta-catenin dependent pathway of Wnt signaling to provide a selective cell anti-proliferative effect. PRI-724 is generated by using the PRISM’s proprietary optimization technology. It was also under development for the treatment of primary biliary cholangitis, choroidal neovascularization, proliferative vitreoretinopathy (PVR), idiopathic pulmonary fibrosis, hematological cancer, colorectal cancer (third line therapy), advanced or metastatic pancreatic adenocarcinoma and metastatic colorectal cancer (first line therapy).

Eisai overview

Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China, and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

For a complete picture of Foscenvivint’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.